BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 27234700)

  • 1. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
    Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
    Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
    Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
    Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
    Sugiyama I; Sadzuka Y
    Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
    Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
    Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal.
    Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG
    ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin encapsulated in micelles enhances radiosensitivity in doxorubicin-resistant tumor cells.
    Xu W; Han M; Diao Y; Pan T; Ge W; Liu H; He H; Jiang H; Zheng S; Zhang S; Gao J; Wei Q
    Discov Med; 2014 Oct; 18(99):169-77. PubMed ID: 25336030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.
    Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS
    J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer.
    Askarizadeh A; Mashreghi M; Mirhadi E; Mehrabian A; Heravi Shargh V; Badiee A; Alavizadeh SH; Arabi L; Kamali H; Jaafari MR
    J Liposome Res; 2024 Jun; 34(2):221-238. PubMed ID: 37647288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
    Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
    Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin.
    Yahuafai J; Asai T; Nakamura G; Fukuta T; Siripong P; Hyodo K; Ishihara H; Kikuchi H; Oku N
    J Control Release; 2014 Oct; 192():167-73. PubMed ID: 25041998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
    Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
    Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.